Literature DB >> 18702606

Young infants can develop protective levels of neutralizing antibody after infection with respiratory syncytial virus.

Joshua J Shinoff1, Katherine L O'Brien, Bhagvanji Thumar, Jana B Shaw, Raymond Reid, Wei Hua, Mathuram Santosham, Ruth A Karron.   

Abstract

Humoral immunity protects against severe respiratory syncytial virus (RSV) disease, but the range and magnitude of antibody responses in RSV-naive children after RSV infection have not been completely defined. We evaluated RSV-neutralizing antibody and immunoglobulin G responses to RSV F and G glycoproteins in 65 RSV-naive Navajo and White Mountain Apache children aged 0-24 months who were hospitalized with RSV infection. In these children, antibody responses developed against RSV F and G and the central conserved region of RSV G. Twenty-seven of 41 infants <6 months old developed reciprocal log(2) RSV neutralizing antibody titers > or =8.0, which correlate with protection of the lower respiratory tract. Multivariate analysis demonstrated that the level of preexisting neutralizing antibody at infection, not age, was the most important factor influencing this response. RSV can induce substantial neutralizing antibody responses in young infants when the titer of preexisting antibodies is low.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18702606     DOI: 10.1086/591460

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  38 in total

1.  Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice.

Authors:  Yoshihiko Murata; Seana C Catherman
Journal:  Vaccine       Date:  2012-06-19       Impact factor: 3.641

2.  Characterization of Pre-F-GCN4t, a Modified Human Respiratory Syncytial Virus Fusion Protein Stabilized in a Noncleaved Prefusion Conformation.

Authors:  Normand Blais; Martin Gagné; Yoshitomo Hamuro; Patrick Rheault; Martine Boyer; Ann-Muriel Steff; Guy Baudoux; Vincent Dewar; Josée Demers; Jean-Louis Ruelle; Denis Martin
Journal:  J Virol       Date:  2017-06-09       Impact factor: 5.103

3.  Antibody response to respiratory syncytial virus infection in children <18 months old.

Authors:  Susanna Esposito; Elisa Scarselli; Mara Lelii; Alessia Scala; Alessandra Vitelli; Stefania Capone; Marco Fornili; Elia Biganzoli; Annalisa Orenti; Alfredo Nicosia; Riccardo Cortese; Nicola Principi
Journal:  Hum Vaccin Immunother       Date:  2016-02-22       Impact factor: 3.452

Review 4.  Vaccine Design Informed by Virus-Induced Immunity.

Authors:  Rhiannon R Penkert; Jane S Hankins; Neal S Young; Julia L Hurwitz
Journal:  Viral Immunol       Date:  2020-05-05       Impact factor: 2.257

Review 5.  Infant Immune Response to Respiratory Viral Infections.

Authors:  Santtu Heinonen; Rosa Rodriguez-Fernandez; Alejandro Diaz; Silvia Oliva Rodriguez-Pastor; Octavio Ramilo; Asuncion Mejias
Journal:  Immunol Allergy Clin North Am       Date:  2019-05-15       Impact factor: 3.479

6.  Respiratory syncytial virus transplacental antibody transfer and kinetics in mother-infant pairs in Bangladesh.

Authors:  Helen Y Chu; Mark C Steinhoff; Amalia Magaret; Khalequ Zaman; Eliza Roy; Gretchen Langdon; Mary Anne Formica; Edward E Walsh; Janet A Englund
Journal:  J Infect Dis       Date:  2014-06-05       Impact factor: 5.226

Review 7.  Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years.

Authors:  Peter L Collins; José A Melero
Journal:  Virus Res       Date:  2011-09-22       Impact factor: 3.303

8.  Infants Infected with Respiratory Syncytial Virus Generate Potent Neutralizing Antibodies that Lack Somatic Hypermutation.

Authors:  Eileen Goodwin; Morgan S A Gilman; Daniel Wrapp; Man Chen; Joan O Ngwuta; Syed M Moin; Patricia Bai; Arvind Sivasubramanian; Ruth I Connor; Peter F Wright; Barney S Graham; Jason S McLellan; Laura M Walker
Journal:  Immunity       Date:  2018-02-03       Impact factor: 31.745

9.  Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.

Authors:  Teresa R Johnson; Christina N Johnson; Kizzmekia S Corbett; Gretchen C Edwards; Barney S Graham
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

10.  Newcastle disease virus-like particles containing respiratory syncytial virus G protein induced protection in BALB/c mice, with no evidence of immunopathology.

Authors:  Matthew R Murawski; Lori W McGinnes; Robert W Finberg; Evelyn A Kurt-Jones; Michael J Massare; Gale Smith; Penny M Heaton; Armando E Fraire; Trudy G Morrison
Journal:  J Virol       Date:  2009-11-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.